ARS Pharmaceuticals, Inc
ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes treatments for severe allergic reactions. The company is involved in the development of neffy, a needle-free and low-dose intranasal epinephrine nasal spray for rescue medication for people with Type I severe allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers. T… Read more
ARS Pharmaceuticals, Inc (SPRY) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.319x
Based on the latest financial reports, ARS Pharmaceuticals, Inc (SPRY) has a cash flow conversion efficiency ratio of -0.319x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-47.05 Million) by net assets ($147.66 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
ARS Pharmaceuticals, Inc - Cash Flow Conversion Efficiency Trend (2018–2024)
This chart illustrates how ARS Pharmaceuticals, Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
ARS Pharmaceuticals, Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of ARS Pharmaceuticals, Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
United Parks & Resorts Inc
NYSE:PRKS
|
-0.307x |
|
ZHEJIANG ASIA-PACIFIC MECHANICAL & ELECTRONIC CO LTD
SHE:002284
|
0.066x |
|
Altarea
LSE:0IRK
|
-0.029x |
|
Sumitomo Pharma Co. Ltd
PINK:SMDPY
|
0.088x |
|
Streamax Technology Co Ltd
SHE:002970
|
0.057x |
|
CVR Energy Inc
NYSE:CVI
|
0.160x |
|
PLUXEE NV
PA:PLX
|
0.434x |
|
Kiwi Property Group Limited
PINK:KWIPF
|
0.025x |
Annual Cash Flow Conversion Efficiency for ARS Pharmaceuticals, Inc (2018–2024)
The table below shows the annual cash flow conversion efficiency of ARS Pharmaceuticals, Inc from 2018 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $256.80 Million | $13.55 Million | 0.053x | +120.54% |
| 2023-12-31 | $230.76 Million | $-59.27 Million | -0.257x | -74.87% |
| 2022-12-31 | $272.89 Million | $-40.08 Million | -0.147x | -126.15% |
| 2021-12-31 | $-31.27 Million | $-17.56 Million | 0.562x | +187.00% |
| 2020-12-31 | $-14.05 Million | $9.07 Million | -0.646x | -119.14% |
| 2019-12-31 | $-5.60 Million | $-18.90 Million | 3.373x | +463.71% |
| 2018-12-31 | $18.20 Million | $-16.88 Million | -0.927x | -- |